Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Regent Pacific Group's Days Payable or its related term are showing as below:
STU:RPG's Days Payable is not ranked *
in the Drug Manufacturers industry.
Industry Median: 90.38 * Ranked among companies with meaningful Days Payable only.
Regent Pacific Group's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Regent Pacific Group Days Payable Related Terms
Regent Pacific Group Days Payable Historical Data
* Premium members only.
The historical data trend for Regent Pacific Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Regent Pacific Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regent Pacific Group Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regent Pacific Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Regent Pacific Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Regent Pacific Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regent Pacific Group (STU:RPG) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Regent Pacific Group and its competitors. According to the industry distribution chart, Regent Pacific Group ranks #999999 out of 927 companies in the Drug Manufacturers industry.
Is Regent Pacific Group's Days Payable too high?
Regent Pacific Group's current Days Payable is 0.00. Based on the distribution chart, Regent Pacific Group ranks #999999 out of 927 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Regent Pacific Group has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Regent Pacific Group's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Regent Pacific Group ranks #999999 out of 927 companies for Days Payable. This places Regent Pacific Group in the lower half of its industry. The industry median Days Payable is 90.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Regent Pacific Group and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regent Pacific Group's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regent Pacific Group stock overvalued right now?
Based on GuruFocus' analysis, Regent Pacific Group (STU:RPG) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.05, compared to a current price of €0.10 — trading 102% above its estimated fair value. The current Days Payable is 0.00. Regent Pacific Group's overall GF Score™ is 16/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Regent Pacific Group (STU:RPG), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regent Pacific Group (STU:RPG) Overvalued in 2026?
Based on GuruFocus' analysis, Regent Pacific Group stock appears to be overvalued.
The current stock price of €0.10 is trading 102% above its estimated GF Value™ of €0.05.
GuruFocus considers Regent Pacific Group to be Significantly Overvalued.
Key valuation signals for STU:RPG:
Days Payable: 0.00
GF Value™: €0.05 vs. price of €0.10 (102% above fair value)
No single metric tells the full story. See the STU:RPG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Geographically, the Europe; U.S.; and Asia Pacific. It derives maximum revenue from Europe.
16GF Score
Get the complete analysis for STU:RPG
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RPG has been successfully added to your 
